

REVIEW ARTICLE

MEDICAL PROGRESS

The Pathophysiology and Treatment of Sepsis

Richard S. Hotchkiss, M.D., and Irene E. Karl, Ph.D.

From the Departments of Anesthesiology (R.S.H.), Medicine (R.S.H., I.E.K.), and Surgery (R.S.H.), Washington University School of Medicine, St. Louis. Address reprint requests to Dr. Hotchkiss at the Department of Anesthesiology, Washington University School of Medicine, Campus Box 8054, St. Louis, MO 63110, or at hotch@morpheus.wustl.edu.

SEPSIS IS THE LEADING CAUSE OF DEATH IN CRITICALLY ILL PATIENTS IN the United States. Sepsis develops in 750,000 people annually, and more than 210,000 of them die.^{1,2} After numerous unsuccessful trials of antiinflammatory agents in patients with sepsis, investigators doubted that mortality could be decreased. Advances in unraveling the pathophysiology and genetic basis for the host response to sepsis have changed the prevailing understanding of the syndrome, and several therapies have demonstrated surprising efficacy. In this article, we examine evolving concepts of sepsis and discuss new and potential therapies.

A DISORDER DUE TO UNCONTROLLED INFLAMMATION?

The prevailing theory has been that sepsis represents an uncontrolled inflammatory response.³⁻⁵ Lewis Thomas popularized this notion when he wrote that “the microorganisms that seem to have it in for us . . . turn out . . . to be rather more like bystanders. . . . It is our response to their presence that makes the disease. Our arsenals for fighting off bacteria are so powerful . . . that we are more in danger from them than the invaders.”⁶ A consensus conference defined sepsis as “the systemic inflammatory response syndrome that occurs during infection.”³ Numerous trials were conducted of agents that block the inflammatory cascade — corticosteroids,⁷ antiendotoxin antibodies,⁸ tumor necrosis factor (TNF) antagonists,^{9,10} interleukin-1-receptor antagonists,¹¹ and other agents.¹² The failure of antiinflammatory agents led investigators to question whether death in patients with sepsis results from uncontrolled inflammation.^{4,13-15} Clinical trials of treatments for sepsis are difficult because of the heterogeneity of patients and the high rates of culture-negative sepsis. Interpretation is complicated, because the analysis of outcomes generates post hoc stratifications that have not been prospectively defined.

The theory that death from sepsis was attributable to an overstimulated immune system was based on studies in animals that do not seem to reflect the clinical picture in humans.¹⁶⁻¹⁸ These studies used large doses of endotoxin or bacteria; consequently, levels of circulating cytokines such as tumor necrosis factor α (TNF- α) were exponentially higher in animals than they are in patients with sepsis.¹⁷ In these studies, the animals died from “cytokine storm,” and compounds and macromolecules that block these mediators improved survival.¹⁶⁻¹⁸

In certain forms of sepsis — for example, meningococemia — circulating TNF- α levels are high and correlate with mortality.^{19,20} Of 55 children with severe infectious purpura (32 of them with *Neisseria meningitidis* infection), 91 percent had elevated levels of circulating TNF- α .¹⁹ Nevertheless, studies have shown that the frequency of an exaggerated systemic inflammatory response is lower than it was originally thought to be.²¹⁻²⁴ Debets et al. reported that only 11 of 43 patients with sepsis had detectable circulating TNF (limit of detection, 5 to 10 pg per milliliter).²¹ In another study of 87 pa-

tients with sepsis, fewer than 10 percent had measurable TNF- α or interleukin-1 β .^{22,23}

Although cytokines are considered to be culprits, they also have beneficial effects in sepsis. Studies in an animal model of peritonitis demonstrated that blocking TNF- α worsens survival.^{25,26} Combination immunotherapy against TNF- α and interleukin-1 receptors was fatal in a neutropenic model of sepsis.²⁷ In clinical trials, a TNF antagonist increased mortality.⁹ The role of TNF- α in combating infection has recently been underscored by the finding that sepsis and other infectious complications developed in patients with rheumatoid arthritis who were treated with TNF antagonists.²⁸

The debate about the merits of inhibiting cytokines in patients with sepsis has been rekindled by a recent trial that indicated that a subgroup of patients with sepsis who had therapy directed against TNF- α had improved survival.²⁹ Also, a meta-analysis of clinical trials of antiinflammatory agents in patients with sepsis showed that although high doses of antiinflammatory agents were generally harmful in such patients, a subgroup of patients (approximately 10 percent) benefited.¹³

Advances in our understanding of cell-signaling pathways that mediate the response to microbes have demonstrated that the concept of blocking endotoxin in order to prevent septic complications may be simplistic. Cells of the innate immune system recognize microorganisms and initiate responses through pattern-recognition receptors called toll-like receptors (TLRs).³⁰⁻³² Insight into the role of TLRs in combating infection has been provided by studies in C3H/HeJ mice,³⁰ which are resistant to endotoxin because of a mutation in the toll-like receptor 4 gene (TLR4). Despite their resistance to endotoxin, these mice have increased mortality with authentic sepsis.^{33,34} TLR4 mutations have been identified in humans and may make persons more susceptible to infection.³⁵ Therefore, although endotoxin has deleterious effects, total blockade of endotoxin may be detrimental. Reasons for the failure of monoclonal antiendotoxin antibodies to improve outcomes in trials involving patients with sepsis are complex.³⁶

FAILURE OF THE IMMUNE SYSTEM?

Patients with sepsis have features consistent with immunosuppression, including a loss of delayed hypersensitivity, an inability to clear infection, and

a predisposition to nosocomial infections.³⁷⁻³⁹ One reason for the failure of antiinflammatory strategies in patients with sepsis may be a change in the syndrome over time. Initially, sepsis may be characterized by increases in inflammatory mediators; but as sepsis persists, there is a shift toward an antiinflammatory immunosuppressive state.^{38,39} There is evidence of immunosuppression in sepsis from studies showing that lipopolysaccharide-stimulated whole blood from patients with sepsis releases markedly smaller quantities of the inflammatory cytokines TNF- α and interleukin-1 β than does that of control patients.⁴⁰ The adverse sequelae of sepsis-induced immunosuppression were reversed with the administration of interferon- γ in patients with sepsis.⁴¹ This immune stimulant restored macrophage TNF- α production and improved survival.⁴¹

MECHANISMS OF IMMUNE SUPPRESSION IN SEPSIS

A SHIFT TO ANTIINFLAMMATORY CYTOKINES

Activated CD4 T cells are programmed to secrete cytokines with either of two distinct and antagonistic profiles.^{42,43} They secrete either cytokines with inflammatory (type 1 helper T-cell [Th1]) properties, including TNF- α , interferon- γ , and interleukin-2, or cytokines with antiinflammatory (type 2 helper T-cell [Th2]) properties — for example, interleukin-4 and interleukin-10 (Fig. 1). The factors that determine whether CD4 T cells have Th1 or Th2 responses are unknown but may be influenced by the type of pathogen, the size of the bacterial inoculum, and the site of infection.⁴² Mononuclear cells from patients with burns or trauma have reduced levels of Th1 cytokines but increased levels of the Th2 cytokines interleukin-4 and interleukin-10, and reversal of the Th2 response improves survival among patients with sepsis.^{38,44} Other studies have demonstrated that the level of interleukin-10 is increased in patients with sepsis and that this level predicts mortality.^{43,45}

ANERGY

Anergy is a state of nonresponsiveness to antigen. T cells are anergic when they fail to proliferate or secrete cytokines in response to their specific antigens. Heidecke et al. examined T-cell function in patients with peritonitis and found that they had decreased Th1 function without increased Th2 cytokine production, which is consistent with anergy.⁴⁶ Defective T-cell proliferation and cytokine secretion




Figure 1. The Response to Pathogens, Involving “Cross-Talk” among Many Immune Cells, Including Macrophages, Dendritic Cells, and CD4 T Cells.

Macrophages and dendritic cells are activated by the ingestion of bacteria and by stimulation through cytokines (e.g., interferon- γ) secreted by CD4 T cells. Alternatively, CD4 T cells that have an antiinflammatory profile (type 2 helper T cells [Th2]) secrete interleukin-10, which suppresses macrophage activation. CD4 T cells become activated by stimulation through macrophages or dendritic cells. For example, macrophages and dendritic cells secrete interleukin-12, which activates CD4 T cells to secrete inflammatory (type 1 helper T-cell [Th1]) cytokines. Depending on numerous factors (e.g., the type of organism and the site of infection), macrophages and dendritic cells will respond by inducing either inflammatory or antiinflammatory cytokines or causing a global reduction in cytokine production (anergy). Macrophages or dendritic cells that have previously ingested necrotic cells will induce an inflammatory cytokine profile (Th1). Ingestion of apoptotic cells can induce either an antiinflammatory cytokine profile or anergy. A plus sign indicates up-regulation, and a minus sign indicates down-regulation; in cases where both a plus sign and a minus sign appear, either up-regulation or down-regulation may occur, depending on a variety of factors.


correlated with mortality.⁴⁶ Patients with trauma or burns have reduced levels of circulating T cells, and their surviving T cells are anergic.⁴⁷


Apoptotic cell death may trigger sepsis-induced anergy. Although the conventional belief was that cells die by necrosis, recent work has shown that cells can die by apoptosis — genetically programmed cell death. In apoptosis, cells “commit suicide” by the activation of proteases that disassemble the cell.^{48,49} Large numbers of lymphocytes and gastrointestinal epithelial cells die by apoptosis during sepsis.⁵⁰⁻⁵² A potential mechanism of lymphocyte apoptosis may be stress-induced endogenous release of glucocorticoids.^{53,54} The type of cell death determines the immunologic function of surviving immune cells (Fig. 1).⁵⁵⁻⁵⁷ Apoptotic cells induce anergy or antiinflammatory cytokines that impair the response to pathogens, whereas necrotic cells cause immune stimulation and enhance antimicrobial defenses (Fig. 1).⁵⁵⁻⁵⁷

DEATH OF IMMUNE CELLS

Autopsy studies in persons who had died of sepsis disclosed a profound, progressive, apoptosis-induced loss of cells of the adaptive immune system.⁵⁰⁻⁵² Although no loss of CD8 T cells, natural killer cells, or macrophages occurred, sepsis markedly decreased the levels of B cells (Fig. 2), CD4 T cells (Fig. 3), and follicular dendritic cells (Fig. 3). The loss of lymphocytes and dendritic cells was especially important, because it occurred during life-threatening infection, when clonal expansion of lymphocytes might have been expected.

The magnitude of the apoptosis-induced loss in lymphocytes during sepsis was apparent in examinations of the circulating lymphocyte count in patients.⁵⁰ In one study, 15 of 19 patients with sepsis had absolute lymphocyte counts below the lower limit of normal (a mean [\pm SD] of 500 ± 270 per cubic millimeter vs. the lower limit of 1200 per cubic millimeter). Losses of B cells, CD4 T cells, and dendrit-





ic cells decrease antibody production, macrophage activation, and antigen presentation, respectively. The potential importance of the depletion of lymphocytes is illustrated by studies in animals showing that prevention of lymphocyte apoptosis improves the likelihood of survival.⁵⁸⁻⁶¹ Immune defects identified in patients with sepsis, including monocyte dysfunction,^{41,62,63} are listed in Table 1.

REAPPRAISAL OF
LEWIS THOMAS'S THEORY

Investigators are challenging Lewis Thomas's theory⁶ that the body's primary response to infec-

tion and injury is uncontrolled hyperinflammation.^{4,13,14,64} Munford and Pugin maintain that the body's normal stress response is activation of anti-inflammatory mechanisms and that, outside of affected tissues, the body's systemic anti-inflammatory responses predominate.⁶⁴ They postulate that immune cells and cytokines have both pathogenic and protective roles and that blocking these mediators may worsen the outcome.⁶⁴ Heidecke et al. examined T-cell function in patients with sepsis and reported that immunosuppression was evident at the onset of sepsis, suggesting a primary hypimmune response.⁴⁶

Weighardt and associates examined lipopoly-

Table 1. Potential Mechanisms of Immune Suppression in Patients with Sepsis.*

Shift from an inflammatory (Th1) to an antiinflammatory (Th2) response
Anergy
Apoptosis-induced loss of CD4 T cells, B cells, and dendritic cells
Loss of macrophage expression of major-histocompatibility-complex class II and costimulatory molecules
Immunosuppressive effect of apoptotic cells

* Th1 denotes type 1 helper T cell, and Th2 type 2 helper T cell.

saccharide-stimulated production of cytokines by monocytes in patients with sepsis that occurred after major visceral surgery.⁶⁵ Postoperative sepsis was associated with the immediate onset of defects in the production of both inflammatory and antiinflammatory cytokines by monocytes, and survival among patients with sepsis correlated with the recovery of the inflammatory but not the antiinflammatory response.⁶⁵ These investigators concluded that immunosuppression was a primary rather than a compensatory response to sepsis.⁶⁵ Others postulate a sequential response to sepsis, with initial marked inflammation followed by immunosuppression.^{14,38,39}

HOST GENETIC FACTORS

On the basis of studies in identical twins and adoptees, genetic factors are known to be major determinants of susceptibility to death from infectious disease.⁶⁶ Some persons have single base-pair alterations (single-nucleotide polymorphisms) in genes controlling the host response to microbes.⁶⁷⁻⁶⁹ Identified alterations include polymorphisms in TNF receptors, interleukin-1 receptors, Fc γ receptors, and TLRs.⁶⁷⁻⁶⁹ Polymorphisms in cytokine genes may determine the concentrations of inflammatory and antiinflammatory cytokines produced and may influence whether persons have marked hyperinflammatory or hypoinflammatory responses to infection. The risk of death among patients with sepsis has been linked to genetic polymorphisms for TNF- α and TNF- β .⁶⁹ Trials examining the effect of polymorphisms in patients with pneumonia and sepsis are under way; such polymorphisms may ultimately be used to identify patients

at high risk for the development of sepsis and organ dysfunction during infection. Thus, physicians may, in the future, be able to use genetic information to dictate immune-based therapy to modulate the response in a given patient.

SURPRISING INSIGHTS ABOUT NEUTROPHILS

Neutrophils have been regarded as double-edged swords in sepsis. Although neutrophils were thought to be essential for the eradication of pathogens, excessive release of oxidants and proteases by neutrophils was also believed to be responsible for injury to organs. Because of the intrapulmonary sequestration of neutrophils and the frequent complication of the acute respiratory distress syndrome in patients with sepsis, this link between overly exuberant neutrophil activation and organ injury was thought to affect the lungs in particular.⁷⁰ Although findings from studies in animals implicated neutrophil-mediated injury, other studies in which granulocyte colony-stimulating factor (G-CSF) was used — to increase the number of neutrophils and enhance their function — demonstrated improved survival among patients with sepsis.

Two randomized trials of G-CSF were conducted in patients with community-acquired and hospital-acquired pneumonia.^{71,72} Despite an increase in the white-cell count to 70,000 per cubic millimeter, there was no evidence of adverse effects on lung function in patients with community-acquired pneumonia.⁷¹ Although a subgroup of patients with multilobar pneumonia had fewer complications and shorter stays in the intensive care unit with G-CSF, there was no improvement in survival. Similarly, hospitalized patients with community-acquired or nosocomial pneumonia who were treated with G-CSF had no survival benefit, no decrease in organ dysfunction, and no decrease in the number of days in intensive care.⁷²

Although marked leukocytosis resulting from G-CSF was not injurious, it is not necessarily possible to extrapolate from such data whether marked leukocytosis would be harmful in patients with severe sepsis. However, these two clinical studies imply that blocking neutrophil function to prevent complications of sepsis would be unlikely to be beneficial. Furthermore, therapies aimed at enhancing the number or function of neutrophils in patients with sepsis are also unlikely to be efficacious.

LESSONS FROM AUTOPSY STUDIES

Autopsy studies in persons who died in the intensive care unit show that the failure to diagnose and appropriately treat infections with antibiotics or surgical drainage is the most common avoidable error.^{73,74} Our laboratory conducted an autopsy study of 20 patients who died in intensive care units⁵⁰; consent was obtained immediately after each patient's death, so that tissues were usually acquired within 30 to 90 minutes after death, thereby permitting tissue morphology to be assessed before autolytic changes occurred. Autopsies were also performed in a control group consisting of patients who had died while critically ill but who did not have clinical sepsis. Immunohistochemical analysis showed that in the majority of patients with sepsis, only two types of cells — lymphocytes and gastrointestinal epithelial cells — were dying; this finding parallels those of studies in animals.^{39,54,75} As had been noted previously, there was a profound loss of cells of the adaptive immune system. Lymphocytes and gastrointestinal epithelial cells normally undergo rapid turnover through apoptosis, and sepsis most likely accelerates these physiologic processes. Focal necrosis occurred in hepatocytes in the region of the central vein (presumably because this region is vulnerable to hypoxia) in 7 of 20 patients, as well as in the brain and heart in 3 patients who had evidence of infarction before death.

CELLULAR HIBERNATION
AS A MECHANISM
OF ORGAN DYSFUNCTION

Another intriguing finding from the autopsy study was a discordance between histologic findings and the degree of organ dysfunction seen in patients who died of sepsis.⁵⁰ Cell death in the heart, kidney, liver, and lung was relatively minor and did not reflect the clinical evidence of more profound organ dysfunction. There was no evidence of injury to cardiac myocytes in patients with sepsis who had myocardial depression. (No patient had meningococemia, which causes myocarditis with infiltration of organisms and granulocytes.) Histologic findings in patients with sepsis and acute renal failure showed only focal injury with preservation of normal glomeruli and renal tubules.⁵⁰ These results are similar to those of studies in patients with acute renal failure in which microscopy showed a dissociation between the degree of tubular necro-

sis and the level of renal dysfunction.^{76,77} Most patients who survive sepsis and acute renal failure recover base-line renal function, suggesting that renal-cell death is not overwhelming during sepsis.⁷⁸

We speculate that much organ dysfunction in patients with sepsis can be explained by "cell hibernation" or "cell stunning," as occurs during myocardial ischemia.⁷⁹ Presumably, sepsis activates defense mechanisms that cause cellular processes to be reduced to basic "housekeeping" roles. A possible molecular basis for cellular stunning was suggested by work from the laboratory of Fink et al.,⁸⁰ who showed that immunostimulated enterocytes have diminished oxygen consumption as a result of depletion of nicotinamide adenine dinucleotide secondary to activation of the nuclear enzyme polyadenosine diphosphate (ADP)-ribose polymerase by peroxynitrite or other oxidants.

DEATH OF PATIENTS WITH SEPSIS

No autopsy studies have revealed why patients with sepsis die. Occasionally, a patient with sepsis may die of refractory shock, but this is exceptional. Although patients with sepsis have profound myocardial depression, cardiac output is usually maintained because of cardiac dilatation and tachycardia.⁸¹ Although the acute respiratory distress syndrome frequently develops in patients with sepsis, such patients rarely die of hypoxemia or hypercarbia.⁸² Renal failure is common, but that alone is not fatal, because dialysis may be used. Liver dysfunction rarely progresses to hepatic encephalopathy. Thus, the exact cause of death in patients with sepsis remains elusive. Many patients die when care is withdrawn or not escalated when families, in consultation with physicians, decide that continued therapy is futile.

NEW CONCEPTS IN THE
TREATMENT OF SEPSIS

Physicians caring for patients in intensive care units need a thorough knowledge of common infectious and noninfectious causes of fever in this population of patients (Table 2). Many patients in whom sepsis develops — for example, elderly patients or patients with uremia — do not become febrile.⁸³ The lack of an apparent acute-phase response in patients with sepsis is associated with high mortality and may reflect the immunosuppressive phase of sepsis. Early manifestations of sepsis include sub-

Table 2. Infectious and Noninfectious Causes of Fever in the Intensive Care Unit.

Infected intravascular catheters
Sinusitis or otitis media (in patients with intranasal devices such as nasogastric tubes or nasal endotracheal tubes)
Acalculous cholecystitis
Drug fever
Pulmonary emboli
Deep venous thrombosis
Central fever (in patients with head trauma)
<i>Clostridium difficile</i> colitis
Postcardiotomy syndrome
Secondary infection by resistant organisms
Fungal infection

tle changes in mental status, minor increases or decreases in white-cell count or neutrophil percentage, or elevated blood glucose levels. Early recognition of sepsis is a key to successful treatment.

ACTIVATED PROTEIN C

Recombinant human activated protein C, an anti-coagulant, is the first antiinflammatory agent that has proved effective in the treatment of sepsis.^{84,85} In patients with sepsis, the administration of activated protein C resulted in a 19.4 percent reduction in the relative risk of death and an absolute risk reduction of 6.1 percent.⁸⁴ Activated protein C inactivates factors Va and VIIIa, thereby preventing the generation of thrombin.⁸⁵ The efficacy of an anti-coagulant agent in patients with sepsis has been attributed to feedback between the coagulation system and the inflammatory cascade.⁸⁵ Inhibition of thrombin generation by activated protein C decreases inflammation by inhibiting platelet activation, neutrophil recruitment, and mast-cell degranulation. Activated protein C has direct antiinflammatory properties, including blocking of the production of cytokines by monocytes and blocking cell adhesion.

A puzzling issue is why activated protein C was successful whereas two other anticoagulants — antithrombin III⁸⁶ and tissue factor–pathway inhibitor — failed as treatments of sepsis. A possible explanation for the failure of these two anticoagulant agents is that they work at different sites in the coagulation cascade. Also, activated protein C has

antiapoptotic actions that may contribute to its efficacy.⁸⁷

The debate regarding the appropriate use of activated protein C, as well as its potential adverse effects, particularly bleeding, has been discussed in recent articles.⁸⁸⁻⁹⁰ A major risk associated with activated protein C is hemorrhage; in a study of activated protein C, 3.5 percent of patients had serious bleeding (intracranial hemorrhage, a life-threatening bleeding episode, or a requirement for 3 or more units of blood), as compared with 2 percent of patients who received placebo ($P < 0.06$). With open-label use of activated protein C after the trial, 13 of 520 patients (2.5 percent) had intracranial hemorrhage.⁸⁸ Caution is advised in the use of activated protein C in patients with an international normalized ratio greater than 3.0 or a platelet count of less than 30,000 per cubic millimeter. Currently, activated protein C is approved only for use in patients with sepsis who have the most severe organ compromise and the highest likelihood of death. Use of activated protein C is restricted in many hospitals to the more seriously ill patients who meet the criteria for sepsis specified by the Acute Physiology and Chronic Health Evaluation (APACHE II) scoring system.

INTENSIVE INSULIN THERAPY FOR HYPERGLYCEMIA

Van den Berghe et al. demonstrated that intensive insulin therapy that maintained the blood glucose level at 80 to 110 mg per deciliter (4.4 to 6.1 mmol per liter) resulted in lower morbidity and mortality among critically ill patients than did conventional therapy that maintained the blood glucose level at 180 to 200 mg per deciliter (10.0 to 11.1 mmol per liter).⁹¹ Intensive insulin therapy reduced the frequency of episodes of sepsis by 46 percent. Patients with bacteremia who were treated with intensive insulin therapy had lower mortality than those who received conventional therapy (12.5 percent vs. 29.5 percent). Insulin therapy reduced the rate of death from multiple-organ failure among patients with sepsis, regardless of whether they had a history of diabetes.

The protective mechanism of insulin in sepsis is unknown. The phagocytic function of neutrophils is impaired in patients with hyperglycemia, and correcting hyperglycemia may improve bacterial phagocytosis. Another potential mechanism involves the antiapoptotic effect of insulin.⁹² Insulin prevents apoptotic cell death from numerous stimu-

li by activating the phosphatidylinositol 3-kinase–Akt pathway.⁹⁰ Regardless of mechanism, it seems reasonable to control blood glucose more tightly in critically ill patients. Clinicians must avert hypoglycemic brain injury in attempting to maintain the blood glucose level at 80 to 110 mg per deciliter. Frequent monitoring of blood glucose is imperative, and studies are needed to determine whether less tight control of blood glucose — for example, a blood glucose level of 120 to 160 mg per deciliter (6.7 to 8.9 mmol per liter) — provides similar benefits.

VOLUME RESUSCITATION

Another recent study by Rivers et al. showed that early aggressive therapy that optimized cardiac preload, afterload, and contractility in patients with severe sepsis and septic shock improved the likelihood of survival.⁹³ Rivers et al. used infusions of colloid or crystalloid, vasoactive agents, and transfusions of red cells to increase oxygen delivery. Resuscitation end points chosen for assessment of the adequacy of oxygen delivery were the normalization of values for mixed venous oxygen saturation, lactate concentration, base deficit, and pH. Patients in the group that received early goal-directed therapy received more fluid, inotropic support, and blood transfusions during the first six hours than did control patients, who received standard resuscitation therapy. During the interval from 7 to 72 hours, patients in the group receiving early goal-directed treatment had a higher mean central venous oxygen concentration, a lower mean lactate concentration, a lower mean base deficit, and a higher mean pH than the control group. Mortality was 30.5 percent in the group receiving early goal-directed treatment, as compared with 46.5 percent in the control group ($P=0.009$). Thus, early therapeutic intervention to restore balance between oxygen delivery and oxygen demand improved survival among patients presenting with severe sepsis. The use of objective measures, including lactate concentration, base deficit, pH, and possibly central venous oxygen saturation, in the follow-up of patients who are receiving resuscitation therapy is advisable.

CORTICOSTEROIDS

Administration of high doses of corticosteroids (e.g., 30 mg of methylprednisolone per kilogram of body weight) does not improve survival among

patients with sepsis and may worsen outcomes by increasing the frequency of secondary infections.⁹⁴ Despite the negative effects of high-dose corticosteroids, a 2001 study by Annane indicated that patients with sepsis who are extremely ill and have persistent shock requiring vasopressors and prolonged mechanical ventilation may benefit from “physiologic” doses of corticosteroids.⁹⁵ It is postulated that such patients may have “relative” adrenal insufficiency despite elevated levels of circulating cortisol.⁹⁶

The proposed explanation for the physiological response to corticosteroids (despite normal or elevated plasma cortisol levels) is desensitization of corticosteroid responsiveness with down-regulation of adrenergic receptors.⁹⁶ Catecholamines increase arterial pressure through effects on adrenergic receptors of the vasculature; corticosteroids increase the expression of adrenergic receptors. Testing involving stimulation by adrenocorticotropic hormones may not be useful in identifying patients with relative adrenal insufficiency. Such patients may have markedly elevated base-line plasma cortisol levels and a blunted response to stimulation by adrenocorticotropic hormones. A random plasma cortisol concentration of less than 20 μg per deciliter suggests an inadequate adrenal response to stress.⁹⁶

A recent study, also by Annane and colleagues, in which hydrocortisone (a 50-mg intravenous bolus four times per day) and fludrocortisone (50 μg per day) were administered for seven days to patients in septic shock showed improved survival in comparison with controls.⁹⁷ Combination therapy was beneficial even in patients with elevated base-line plasma cortisol levels if their serum cortisol level did not increase by more than 9 μg per deciliter when stimulated by adrenocorticotropic hormone. Somewhat worrisome was the fact that patients who did not have adrenal insufficiency and who received corticosteroids had a slight, albeit not statistically significant, trend toward increased mortality.⁹⁸ A second issue that has been raised is the high mortality rate in the population of patients — 63 percent in the placebo group. In summary, clinicians should not use high-dose corticosteroids in patients with sepsis. Low-dose hydrocortisone was effective in one study in patients with septic shock, but that finding has not been confirmed by other groups.

AN EMERGING CONCEPT
OF THE NATURE OF THE
IMMUNE RESPONSE IN SEPSIS

Our current hypothesis regarding the activity of the immune system during sepsis is illustrated in Figure 4, which depicts the responses of three hypothetical patients. The type of response is determined by many factors, including the virulence of the organism, the size of the inoculum, and the patient's coexisting conditions, nutritional status, age, and polymorphisms in cytokine genes or other immune-effector molecules or their receptors.

Our evaluation of spleens removed after the death of patients with sepsis demonstrated that the more prolonged the sepsis, the more profound was the loss of B cells and CD4 T cells.⁵¹ Most deaths occurred during the prolonged hypoinflammatory state, and reversal or prevention of this immune deficiency should be a major focus of research. Antiinflammatory strategies applied early in patients with a hyperinflammatory immune response may be life-saving.^{13,14,29,78,84} In addition to TNF- α and interleukin-1 β , other inflammatory mediators may have critical roles in mediating cell injury in sepsis. Recently, high-mobility group 1 protein was identified as a late mediator of the lethality of endotoxin in mice and has correlated with outcome in patients with sepsis.^{99,100}

Measurement of circulating concentrations of inflammatory mediators may prove to be useful in evaluating the stage of sepsis and in tailoring the administration of antiinflammatory agents. Alternatively, antiinflammatory agents used during the hypoinflammatory phase may worsen outcome.^{9,13,39} When patients are determined to be in a hypoinflammatory state, inflammatory strategies that enhance the function of the innate or adaptive immune system may be found to be efficacious.^{15,39,43} The ability of interferon- γ , a potent macrophage activator, to improve survival in a subgroup of patients with sepsis may be the first example of immune-enhancing therapy for sepsis.⁴¹ Interferon- γ was found to restore macrophage HLA-DR expression and TNF- α production in patients with sepsis.

POTENTIAL THERAPIES FOR SEPSIS

Diverse new agents have shown efficacy in clinically relevant animal models and offer hope as well as new insight into sepsis. O'Suilleabhain et al. noted that interleukin-12, a potent immune stimulant and




Figure 4. Immunologic Response of Three Hypothetical Patients with Sepsis.

The individual response is determined by many factors, including the virulence of the organism, the size of the inoculum, and the patient's coexisting conditions, age, and polymorphisms in genes for cytokines. The initial immune response is hyperinflammatory, but the response rapidly progresses to hypoinflammatory. A secondary bump in the hyperimmune state can occur during the hospital course with secondary infections. In the hypothetical healthy person who has contracted a serious meningococcal infection, there is an initial robust hyperinflammatory response. This patient would have extremely high plasma concentrations of TNF- α and other inflammatory cytokines. Death may occur due to a hyperinflammatory state, and antiinflammatory treatments may improve the likelihood of survival. If infection resolves rapidly, there is only a minimal hypoinflammatory state. In the hypothetical elderly malnourished person with diverticulitis, the initial response is limited, and, if infection persists, a prolonged hypoinflammatory response develops, followed by either recovery or death. In the hypothetical patient with diabetes, chronic renal failure, and pneumonia, the initial response is blunted, and there is prolonged depression of immune function, culminating in death.

Th1 inducer, reduced mortality from subsequent sepsis when administered after burn injury.¹⁰¹ Administration of antibodies against complement-activation product C5a decreased the frequency of bacteremia, prevented apoptosis, and improved survival.¹⁰²⁻¹⁰⁴ Calandra and associates reported that high concentrations of macrophage inhibitory factor were present in patients with sepsis and that the administration of antibodies against macrophage migration inhibitory factor protected mice from peritonitis.¹⁰⁵ Strategies that block apoptosis of lymphocytes or gastrointestinal epithelial cells have improved survival in experimental models of

sepsis.^{58-61,106,107} Mice with sepsis that are deficient in poly-ADP-ribose polymerase 1 (PARP) have improved survival, and administration of a PARP inhibitor was beneficial in pig models.^{108,109} The central nervous system is an important modulator of inflammation; electrical stimulation of the vagus nerve protects against endotoxemic shock.¹¹⁰ Thus, a variety of agents hold promise as effective new therapies for sepsis.

CONCLUSIONS

A major shift has occurred in the way investigators view the problem of sepsis. Sepsis may not be attributable solely to an "immune system gone haywire" but may indicate an immune system that is severely compromised and unable to eradicate pathogens. Mechanisms of organ failure and death in patients with sepsis remain unknown, and autopsy studies do not reveal widespread necrosis. Current clinical

advances in the treatment of sepsis include therapy with activated protein C, tight control of blood glucose, and early goal-directed therapy to treat the cellular oxygen deficit. Future therapy may be directed at enhancing or inhibiting the patient's immune response, depending on genetic polymorphisms, the duration of disease, and the characteristics of the particular pathogen.

Supported by grants (GM 44118 and GM 55194) from the National Institutes of Health and by the Alan A. and Edith L. Wolff Foundation.

Dr. Hotchkiss has reported receiving grant support from Merck Frosst.

We are indebted to Kevin W. Tinsley, Katherine C. Chang, Dale F. Osborne, Christopher G. Davis, Thomas Howard, and Nemani Rateri for their dedication and skills; to our colleagues Paul E. Swanson, Timothy G. Buchman, J. Perren Cobb, Craig Coopersmith, Bradley D. Freeman, and Robert E. Schmieg for their contributions to the formulation of the ideas expressed in this review; to Gordon R. Bernard for helpful discussions regarding the manuscript; and to the nurses and staff members of the 8400 surgical intensive care unit at Barnes Jewish Hospital.

REFERENCES

- Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001;29:1303-10.
- Murphy SL. Deaths: final data for 1998. National vital statistics report. Vol. 48. No. 11. Hyattsville, Md.: National Center for Health Statistics, 2000. (DHHS publication no. (PHS) 2000-1120 0-0487.)
- Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest* 1992;101:1644-55.
- Warren HS. Strategies for the treatment of sepsis. *N Engl J Med* 1997;336:952-3.
- Stone R. Search for sepsis drugs goes on despite past failures. *Science* 1994;264:365-7.
- Thomas L. Germs. *N Engl J Med* 1972;287:553-5.
- Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. *N Engl J Med* 1987;317:653-8.
- Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. *N Engl J Med* 1991;324:429-36.
- Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. *N Engl J Med* 1996;334:1697-702.
- Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal anti-body to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. *JAMA* 1995;273:934-41.
- Fisher CJ Jr, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. *Crit Care Med* 1994;22:12-21.
- Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. *N Engl J Med* 1997;336:912-8.
- Zeni F, Freeman BF, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. *Crit Care Med* 1997;25:1095-100.
- Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. *Ann Intern Med* 1994;120:771-83.
- Nelson S. A question of balance. *Am J Respir Crit Care Med* 1999;159:1365-7.
- Fink MP, Heard SO. Laboratory models of sepsis and septic shock. *J Surg Res* 1990;49:186-96.
- Deitch EA. Animal models of sepsis and shock: a review and lessons learned. *Shock* 1998;9:1-11.
- O'Reilly M, Newcomb DE, Remick D. Endotoxin, sepsis, and the primrose path. *Shock* 1999;12:411-20.
- Girardin E, Grau GE, Dayer J-M, Roux-Lombard P, J5 Study Group, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. *N Engl J Med* 1988;319:397-400.
- Hatherill M, Tibby SM, Turner C, Ratanavel N, Murdoch IA. Procalcitonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. *Crit Care Med* 2000;28:2591-4.
- Debets JMH, Kampmeijer R, van der Linden MPMH, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. *Crit Care Med* 1989;17:489-94.
- Oberholzer C, Oberholzer C, Moldawer LL. Cytokine signaling — regulation of the immune response in normal and critically ill states. *Crit Care Med* 2000;28:Suppl:N3-N12.
- Pruitt JH, Welborn MB, Edwards PD, et al. Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. *Blood* 1996;87:3282-8.
- Rogy MA, Coyle SM, Oldenburg HS, et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. *J Am Coll Surg* 1994;178:132-8.
- Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. *J Immunol* 1992;148:2724-30.
- Echtenacher B, Weigl K, Lehn N, Manne DN. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. *Infect Immun* 2001;69:3550-5.
- Opal SM, Cross AS, Jhung JW, et al. Potential hazards of combination immunotherapy in the treatment of experimental septic shock. *J Infect Dis* 1996;173:1415-21.

28. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α -neutralizing agent. *N Engl J Med* 2001;345:1098-104.
29. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. *Crit Care Med* 2001;29:Suppl:S121-S125.
30. Modlin RL, Brightbill HD, Godowski PJ. The toll of innate immunity on microbial pathogens. *N Engl J Med* 1999;340:1834-5.
31. Vasselon T, Detmers PA. Toll receptors: a central element in innate immune responses. *Infect Immun* 2002;70:1033-41.
32. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. *Curr Opin Immunol* 2002;14:103-10.
33. Hagberg L, Briles DE, Eden CS. Evidence for separate genetic defects in C3H/HeJ and C3HeB/FeJ mice, that affect susceptibility to gram-negative infections. *J Immunol* 1985;134:4118-22.
34. Hotchkiss RS, Swanson PE, Knudson CM, et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. *J Immunol* 1999;162:4148-56.
35. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. *Nat Genet* 2000;25:187-91.
36. Warren HS, Amato SE, Fitting C, et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. *J Exp Med* 1993;177:89-97.
37. Meakins JL, Pietsch JB, Bubenick O, et al. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. *Ann Surg* 1977;186:241-50.
38. Lederer JA, Rodrick ML, Mannick JA. The effects of injury on the adaptive immune response. *Shock* 1999;11:153-9.
39. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. *Shock* 2001;16:83-96.
40. Ertel W, Kremer J-P, Kenney J, et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. *Blood* 1995;85:1341-7.
41. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. *Nat Med* 1997;3:678-81.
42. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. *Nature* 1996;383:787-93.
43. Opal SM, DePalo VA. Anti-inflammatory cytokines. *Chest* 2000;117:1162-72.
44. O'Sullivan ST, Lederer JA, Horgan AF, Chin DHL, Mannick JA, Rodrick ML. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. *Ann Surg* 1995;222:482-92.
45. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. *J Infect Dis* 2000;181:176-80.
46. Heidecke C-D, Hensler T, Weighardt H, et al. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. *Am J Surg* 1999;178:288-92.
47. Pellegrini JD, De AK, Kodys K, Puyana JC, Furse RK, Miller-Graziano C. Relationships between T lymphocyte apoptosis and anergy following trauma. *J Surg Res* 2000;88:200-6.
48. Raff M. Cell suicide for beginners. *Nature* 1998;396:119-22.
49. Haslett C, Savill J. Why is apoptosis important to clinicians? *BMJ* 2001;322:1499-500.
50. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. *Crit Care Med* 1999;27:1230-51.
51. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. *J Immunol* 2001;166:6952-63.
52. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. *J Immunol* 2002;168:2493-500.
53. Fukuzuka K, Edwards CK III, Clare-Salzler M, Copeland EM III, Moldawer LL, Mozingo DW. Glucocorticoid-induced, caspase-dependent organ apoptosis early after burn injury. *Am J Physiol Regul Integr Comp Physiol* 2000;278:R1005-R1018.
54. Ayala A, Herdon CD, Lehman DL, DeMaso CM, Ayala CA, Chaudry IH. The induction of accelerated thymic programmed cell death during polymicrobial sepsis: control by corticosteroids but not tumor necrosis factor. *Shock* 1995;3:259-67.
55. Green DR, Beere HM. Apoptosis: gone but not forgotten. *Nature* 2000;405:28-9.
56. Voll RE, Herrmann M, Roth EA, Stach C, Kalten JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. *Nature* 1997;390:350-1.
57. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. *Nature* 2000;405:85-90.
58. Chung CS, Xu YX, Wang W, Chaudry IH, Ayala H. Is Fas ligand or endotoxin responsible for mucosal lymphocyte apoptosis in sepsis? *Arch Surg* 1998;133:1213-20.
59. Oberholzer C, Oberholzer A, Bahjat FR, et al. Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. *Proc Natl Acad Sci U S A* 2001;98:11503-8.
60. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. *Proc Natl Acad Sci U S A* 1999;96:14541-6.
61. Hotchkiss RS, Chang KC, Swanson PE, et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. *Nat Immunol* 2000;1:496-501.
62. Manjuck J, Saha DC, Astiz M, Eales LJ, Rackow EC. Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients. *J Lab Clin Med* 2000;135:153-60.
63. Ertel W, Morrison MH, Ayala A, Dean RE, Chaudry IH. Interferon-gamma attenuates hemorrhage-induced suppression of macrophage and splenocyte functions and decreases susceptibility to sepsis. *Surgery* 1992;111:177-87.
64. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. *Am J Respir Crit Care Med* 2001;163:316-21.
65. Weighardt H, Heidecke C-D, Emmanuilelidis K, et al. Sepsis after major visceral surgery is associated with sustained and interferon- γ -resistant defects of monocyte cytokine production. *Surgery* 2000;127:309-15.
66. Sørensen TIA, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. *N Engl J Med* 1988;318:727-32.
67. van Deventer SJ. Cytokine and cytokine receptor polymorphisms in infectious disease. *Intensive Care Med* 2000;26:Suppl 1: S98-S102.
68. van der Pol WL, Huizinga TW, Vidarsson G, et al. Relevance of Fc γ receptor and interleukin-10 polymorphisms for meningococcal disease. *J Infect Dis* 2001;184:1548-55.
69. Freeman BD, Buchman TG. Gene in a haystack: tumor necrosis factor polymorphisms and outcome in sepsis. *Crit Care Med* 2000;28:3090-1.
70. Kollef MH, Schuster DP. The acute respiratory distress syndrome. *N Engl J Med* 1995;332:27-37.
71. Nelson S, Belknap SM, Carlson RW, et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. *J Infect Dis* 1998;178:1075-80.
72. Root RK, Marrie TJ, Lodato RF, et al. A multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. *Crit Care Med* (in press).
73. Mort T, Yeston NS. The relationship of pre mortem diagnoses and post mortem findings in a surgical intensive care unit. *Crit Care Med* 1999;27:299-303.
74. Blosser SA, Zimmerman HE, Stauffer JL. Do autopsies of critically ill patients reveal important findings that were clinically undetected? *Crit Care Med* 1998;26:1332-6.
75. Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, Karl IE. Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and

- B-cell-deficient mice. *Crit Care Med* 1997; 25:1298-307.
76. Weinberg JM, Venkatachalam MA. Guanine nucleotides and acute renal failure. *J Clin Invest* 2001;108:1279-81.
77. Solez K, Morel-Maroger L, Sraer JD. The morphology of "acute tubular necrosis" in man: analysis of 57 renal biopsies and a comparison with the glycerol model. *Medicine (Baltimore)* 1979;58:362-76.
78. Wheeler AP, Bernard GR. Treating patients with severe sepsis. *N Engl J Med* 1999;340:207-14.
79. Sawyer DB, Loscalzo J. Myocardial hibernation: restorative or preterminal sleep? *Circulation* 2002;105:1517-9.
80. Khan AU, Delude RL, Han YY, et al. Liposomal NAD(+) prevents diminished O(2) consumption by immunostimulated Caco-2 cells. *Am J Physiol Lung Cell Mol Physiol* 2002;282:L1082-L1091.
81. Parrillo JE. Pathogenetic mechanisms of septic shock. *N Engl J Med* 1993;328:1471-7.
82. Bell RC, Coalson JJ, Smith JD, Johanson WG Jr. Multiple organ system failure and infection in adult respiratory distress syndrome. *Ann Intern Med* 1983;99:293-8.
83. Gleckman R, Hibert D. Afebrile bacteremia: a phenomenon in geriatric patients. *JAMA* 1982;248:1478-81.
84. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001;344:699-709.
85. Matthay MA. Severe sepsis — a new treatment with both anticoagulant and anti-inflammatory properties. *N Engl J Med* 2001;344:759-62.
86. Warren BL, Eid A, Singer P, et al. High-dose antithrombin III in severe sepsis: a randomized controlled trial. *JAMA* 2001;286:1869-78. [Erratum, *JAMA* 2002;287:192.]
87. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. *J Biol Chem* 2001;276:11199-203.
88. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. *N Engl J Med* 2002;347:1027-30.
89. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. *N Engl J Med* 2002;347:993-1000.
90. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. *N Engl J Med* 2002;347:1030-4.
91. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001;345:1359-67.
92. Gao F, Gao E, Yue TL, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. *Circulation* 2002;105:1497-502.
93. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001;345:1368-77.
94. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. *Crit Care Med* 1995;23:1430-9.
95. Annane D. Corticosteroids for septic shock. *Crit Care Med* 2001;29:Suppl:S117-S120.
96. Shenker Y, Skatrud JB. Adrenal insufficiency in critically ill patients. *Am J Respir Crit Care Med* 2001;163:1520-3.
97. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002;288:862-71.
98. Abraham E, Evans T. Corticosteroids and septic shock. *JAMA* 2002;288:886-7.
99. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. *Science* 1999;285:248-51.
100. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. *J Exp Med* 2000;192:565-70.
101. O'Suilleabhain C, O'Sullivan ST, Kelly JL, Lederer J, Mannick JA, Rodrick ML. Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury. *Surgery* 1996;120:290-6.
102. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. *Nat Med* 1999;5:788-92.
103. Guo RF, Huber-Lang M, Wang X, et al. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. *J Clin Invest* 2000;106:1271-80.
104. Huber-Lang MS, Sarma JV, McGuire SR, et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. *FASEB J* 2001;15:568-70.
105. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. *Nat Med* 2000;6:164-70.
106. Coopersmith C, Stromberg PR, Dunne WM, et al. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. *JAMA* 2002; 287:1716-21.
107. Oberholzer C, Oberholzer A, Clare-Salzler M, Moldawer LL. Apoptosis in sepsis: a new target for therapeutic exploration. *FASEB J* 2001;15:879-92.
108. Soriano FG, Liaudet L, Szabo E, et al. Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. *Shock* 2002;17:286-92.
109. Goldfarb RD, Marton A, Szabo E, et al. Protective effect of a novel, potent inhibitor of poly(adenosine 5'-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. *Crit Care Med* 2002;30:974-80.
110. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* 2000;405:458-62.

Copyright © 2003 Massachusetts Medical Society.